Compounds > levodopa
Page last updated: 2024-08-17

levodopa and sarizotan

levodopa has been researched along with sarizotan in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (66.67)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bibbiani, F; Chase, TN; Oh, JD1
Chassard, D; Kovar, A; Krösser, S; Neugebauer, R1
Aguilar, E; Bartoszyk, GD; Marin, C; Obeso, JA; Rodríguez-Oroz, MC1
Bartoszyk, GD; Bédard, PJ; Di Paolo, T; Graham, J; Grégoire, L; Samadi, P1
Bartoszyk, GD; Dean, O; Gerlach, M; Riederer, P; van den Buuse, M1
Egeland, M; Svenningsson, P; Zhang, X1

Trials

1 trial(s) available for levodopa and sarizotan

ArticleYear
Investigation of the impact of sarizotan on the pharmacokinetics of levodopa.
    Biopharmaceutics & drug disposition, 2007, Volume: 28, Issue:7

    Topics: Adult; Cross-Over Studies; Drug Interactions; Humans; Levodopa; Male; Organic Chemicals

2007

Other Studies

5 other study(ies) available for levodopa and sarizotan

ArticleYear
Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models.
    Neurology, 2001, Nov-27, Volume: 57, Issue:10

    Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dose-Response Relationship, Drug; Female; Levodopa; Macaca fascicularis; Male; Motor Skills; Organic Chemicals; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Species Specificity; Stereotyped Behavior; Substantia Nigra

2001
Local administration of sarizotan into the subthalamic nucleus attenuates levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
    Psychopharmacology, 2009, Volume: 204, Issue:2

    Topics: Animals; Apomorphine; Benserazide; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; Immunohistochemistry; Levodopa; Male; Microinjections; Organic Chemicals; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Rotation; Serotonin Receptor Agonists; Stereotyped Behavior; Subthalamic Nucleus; Sympathectomy, Chemical; Sympatholytics

2009
Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Parkinsonism & related disorders, 2009, Volume: 15, Issue:6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Female; Levodopa; Macaca fascicularis; Organic Chemicals; Ovariectomy; Parkinsonian Disorders; Serotonin Receptor Agonists

2009
Role of dopamine D3 and serotonin 5-HT 1A receptors in L: -DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2011, Volume: 118, Issue:12

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Dyskinesia, Drug-Induced; Levodopa; Male; Organic Chemicals; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D3; Serotonin 5-HT1 Receptor Agonists; Time Factors

2011
Antidepressant-like properties of sarizotan in experimental Parkinsonism.
    Psychopharmacology, 2011, Volume: 218, Issue:4

    Topics: Animals; Antidepressive Agents; Antiparkinson Agents; Behavior, Animal; Benserazide; Cell Proliferation; Dentate Gyrus; Depression; Disease Models, Animal; Doublecortin Protein; Drug Combinations; Levodopa; Locomotion; Male; Organic Chemicals; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Swimming

2011